The United States Patent and Trademark Office (USPTO) has issued patent US12583937B2 to Genentech, Inc. This patent covers compositions of matter and methods for diagnosing and treating tumors in mammals. The patent was filed on March 16, 2022, and has an effective grant date of March 24, 2026, with 6 claims.

This patent grant is primarily an informational notice for entities involved in pharmaceutical research and development. While it does not impose new regulatory obligations, it signifies intellectual property protection for specific diagnostic and therapeutic technologies in oncology. Companies operating in this space, particularly those developing peptide-based therapeutics or diagnostic tools, should be aware of this granted patent and its potential implications for their research and commercialization strategies.